High variation of individual soluble serum CD30 levels of pre-transplantation patients: sCD30 a feasible marker for prediction of kidney allograft rejection?

Nephrology Dialysis Transplantation

Volumn 22, Issue 10, 2007, Pages 2795-2799

  Altermann, Wolfgang ^a   Schlaf, Gerald ^a   Rothhoff, Anita ^a   Seliger, Barbara ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Graft survival; Haemodialysis; Kidney transplantation; Soluble CD30

Indexed keywords

CD30 ANTIGEN;

ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ANTIGENS, CD30; ENZYME-LINKED IMMUNOSORBENT ASSAY; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; RENAL DIALYSIS; REPRODUCIBILITY OF RESULTS; RISK; SPECIMEN HANDLING; TIME FACTORS; TREATMENT OUTCOME;

EID: 36049016142     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm397     Document Type: Article

References (19)

1. Schwab U, Stein H, Gerdes J et al. Production of monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkińs disease and a subset of normal lymphoid cells. Nature 1982; 299: 65-67
2. Pizzolo G, Vinante F, Chilosi M et al. Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin's disease. Relationship with disease activity and clinical stage. Br J Haemtol 1990; 75: 282-284
3. Nadali G, Vinante F, Ambrosetti A et al. Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis. J Clin Oncol 1994; 12: 793-797
4. Kennedy MK, Willis CR, Armitage RJ. Deciphering CD30 ligand biology and its role in humoral immunity. Immunology 2006; 118: 143-152
5. Pelzl S, Opelz G, Wiesel M et al. Soluble CD30 as a predictor of kidney graft outcome. Transplantation 2002; 73: 3-6
6. Suesal C, Pelzl S, Doehler B, Opelz G. Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J Am Soc Nephrol 2002; 13: 1650-1656
7. Suesal C, Pelzl S, Opelz G. Strong human leukocyte antigen matching effect in nonsensitized kidney recipients with high pretransplant soluble CD30. Transplantation 2003; 76: 1231-1232
8. Cinti P, Pretagostini R, Arpino A et al. Evaluation of pretransplant immunologic status in kidney-transplant recipients by panel reactive antibody and soluble CD30 determinations. Transplantation 2005; 79: 1154-1156
9. Barbano G, Cappa F, Prigione I et al. Plasma levels of soluble CD30 are increased in children with chronic renal failure and with primary growth deficiency and decrease during treatment with recombinant human growth hormone. Nephrol Dial Transplant 2001; 16: 1807-1813
10. Sengul S, Keven K, Gormez U, Kutlay S, Erturk S, Erbay B. Identification of patients at risk of acute rejection by pretransplantation and posttransplantation monitoring of soluble CD30 levels in kidney transplantation. Transplantation 2006; 81: 1216-1219
11. Nakao K, Nagake Y, Okamoto A, Ichikawa H, Yamamura M, Makino H. Serum levels of soluble CD26 and CD30 in patients on hemodialysis. Nephron 2002; 91: 215-221
12. Descamps-Latscha B, Herbelin A. Long-term dialysis and cellular immunity: a critical survey. Kidney Int 1993; 43: 135-142
13. Descamps-Latscha B, Chatenoud L. T cells and B cells in chronic renal failure. Semin Nephrol 1996; 16: 183-191
14. Taskapan H, Utas C, Oymak FS, Guelmez I, Oezesmi M. The outcome of tuberculosis in patients on chronic hemodialysis. Clin Nephrol 2000; 54: 134-137
15. Rajakariar R, Jivanji N, Varagunam L et al. High pre-transplant soluble CD30 levels are predictive of the grade of rejection. Am J Transpl 2005; 5: 1922-1925
16. Slavcev A, Lacha J, Honsova E et al. Soluble CD30 and HLA antibodies as potential risk factors for kidney transplant rejection. Transpl Immunol 2005; 14: 117-121
17. Dong W, Shunliang Y, Weizhen W et al. Prediction of acute renal allograft rejection in early post-transplantation period by soluble CD30. Transpl Immunol 2006; 16: 41-45
18. Roy R, Dugre FJ, Berube L, Langlois S, Lachance JG. CD30 and TNF-alpha serum level as indicators of ongoing acute kidney graft rejection. Hum Immunol 2002; 63: 75
19. Pelzl S, Opelz G, Daniel V, Wiesel M, Suesal C. Evaluation of posttransplantation soluble CD30 for diagnosis of acute renal allograft rejection. Transplantation 2003; 75: 421-423